162 related articles for article (PubMed ID: 37896797)
21. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
Kim S; Liu Y; Lei Z; Dicker J; Cao Y; Zhang XF; Im W
J Chem Theory Comput; 2021 Dec; 17(12):7972-7979. PubMed ID: 34856802
[TBL] [Abstract][Full Text] [Related]
22. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells.
Zheng L; Ma Y; Chen M; Wu G; Yan C; Zhang XE
Biochem Biophys Res Commun; 2021 Nov; 579():69-75. PubMed ID: 34592572
[TBL] [Abstract][Full Text] [Related]
24. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
Saiz ML; DeDiego ML; López-García D; Corte-Iglesias V; Baragaño Raneros A; Astola I; Asensi V; López-Larrea C; Suarez-Alvarez B
Clin Epigenetics; 2021 Oct; 13(1):187. PubMed ID: 34635175
[TBL] [Abstract][Full Text] [Related]
26. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
27. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
28. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.
Frolova EI; Palchevska O; Lukash T; Dominguez F; Britt W; Frolov I
J Virol; 2022 Aug; 96(15):e0075322. PubMed ID: 35876526
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems.
Zhang F; Li W; Feng J; Ramos da Silva S; Ju E; Zhang H; Chang Y; Moore PS; Guo H; Gao SJ
J Med Virol; 2021 Dec; 93(12):6671-6685. PubMed ID: 34324210
[TBL] [Abstract][Full Text] [Related]
30. Broad Tricyclic Ring Inhibitors Block SARS-CoV-2 Spike Function Required for Viral Entry.
Ratnapriya S; Braun AR; Cervera Benet H; Carlson D; Ding S; Paulson CN; Mishra N; Sachs JN; Aldrich CC; Finzi A; Herschhorn A
ACS Infect Dis; 2022 Oct; 8(10):2045-2058. PubMed ID: 36153947
[TBL] [Abstract][Full Text] [Related]
31. TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein.
Kishimoto M; Uemura K; Sanaki T; Sato A; Hall WW; Kariwa H; Orba Y; Sawa H; Sasaki M
Viruses; 2021 Feb; 13(3):. PubMed ID: 33671076
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
33. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
34. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
[TBL] [Abstract][Full Text] [Related]
35. Contemporary Circulating Enterovirus D68 Strains Have Acquired the Capacity for Viral Entry and Replication in Human Neuronal Cells.
Brown DM; Hixon AM; Oldfield LM; Zhang Y; Novotny M; Wang W; Das SR; Shabman RS; Tyler KL; Scheuermann RH
mBio; 2018 Oct; 9(5):. PubMed ID: 30327438
[TBL] [Abstract][Full Text] [Related]
36. Spike protein mediated membrane fusion during SARS-CoV-2 infection.
Li X; Yuan H; Li X; Wang H
J Med Virol; 2023 Jan; 95(1):e28212. PubMed ID: 36224449
[TBL] [Abstract][Full Text] [Related]
37. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection.
Trbojević-Akmačić I; Petrović T; Lauc G
Glycoconj J; 2021 Oct; 38(5):611-623. PubMed ID: 34542788
[TBL] [Abstract][Full Text] [Related]
39. Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors.
Ma L; Li Y; Shi T; Zhu Z; Zhao J; Xie Y; Wen J; Guo S; Wang J; Ding J; Liang C; Shan G; Li Q; Ge M; Cen S
Biomed Pharmacother; 2023 Feb; 158():114213. PubMed ID: 36916436
[TBL] [Abstract][Full Text] [Related]
40. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
Hoffmann M; Sidarovich A; Arora P; Krüger N; Nehlmeier I; Kempf A; Graichen L; Winkler MS; Niemeyer D; Goffinet C; Drosten C; Schulz S; Jäck HM; Pöhlmann S
mBio; 2022 Jun; 13(3):e0036422. PubMed ID: 35467423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
